What Orchestra Life Sciences does

Orchestra Life Sciences is a privately held technical consultancy founded in 2022 and headquartered at the Philadelphia Navy Yard, serving pharmaceutical and biotechnology companies developing radiopharmaceuticals, cell and gene therapies, regenerative medicines, and nuclear medicine products for cancer and rare disease. The firm deploys subject matter experts and consultants to deliver end-to-end support across seven integrated service lines: business strategy, engineering solutions, process and analytical development, capital projects, supply chain, quality and regulatory, and operations excellence. Its team brings over 500 years of combined nuclear medicine expertise and 100+ years in cell and gene therapy, with senior leadership including co-founders Emilie Pelletier (CEO), Sumit Verma, and Castor Armesto (CSO), plus a European President drawn from NRG's Executive Board.

The company's core technology and intellectual property center on advanced therapy manufacturing readiness, including facility design for hot cells, cyclotrons, isolators, containment systems, and process skids, as well as a proprietary TAG1 Generator intended to unlock Lead-212 (Pb-212) supply for targeted alpha therapy trials in collaboration with Precirix. Revenue is generated through professional services engagements, project-based work, and ongoing advisory relationships with enterprise clients, with pricing quote-based and not publicly disclosed. Strategic partnerships with Life Couriers (radiopharma logistics) and BioCentriq ($12M CAPEX cell therapy facility) extend the firm beyond pure advisory into integrated delivery.

In 2025–2026, Orchestra relocated from Montreal to Philadelphia's Navy Yard, expanded into Europe under a dedicated President, and announced a 2026 Workforce Development Center to address a documented nationwide shortage of 400–600 production operators and 400–800 QA/QC technicians in advanced therapy manufacturing. The firm operates as an LLC, is founder-owned without disclosed institutional investment, and supports 30+ life sciences clients across North America and Europe.

Name

Orchestra Life Sciences

Legal name

Orchestra Life Sciences, LLC

Website

https://orchestralifesciences.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Life Sciences Technical Consulting

NAICS

Other Scientific and Technical Consulting Services (54169), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC) (HLAGAKAB)

akta.pro secondary industry

CMC, Process Development & Tech Transfer Staffing FSP (HLAGAOAK)

Keywords

• Pharmaceutical consulting services
• Radiopharmaceutical manufacturing
• Cell gene therapy consulting
• Advanced therapy manufacturing
• GMP regulatory compliance

Headquarters

HQ city

Chesterfield

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technical Consulting Services: The company provides strategic support and scientific expertise to advance pharmaceutical therapies for cancer and rare disease. Services include business strategy, engineering solutions, process and analytical development, capital projects, supply chain, quality and regulatory, and operations excellence. Revenue is generated through consulting engagements, project-based work, and ongoing advisory relationships with clients in the advanced therapy sector.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Orchestra Life Sciences is a technical consultancy providing strategic support and scientific expertise to pharmaceutical companies developing advanced therapies. Its core offering spans seven integrated service lines—Business Strategy, Engineering Solutions, Process & Analytical Development, Capital Projects, Supply Chain, Quality & Regulatory, and Operations Excellence—delivered alongside an ATMP Laboratory Services division and a Workforce Development Center for advanced therapy manufacturing talent.

Product overview

Orchestra Life Sciences is a technical consultancy offering a unified portfolio of strategic and scientific services organized around the core mission of advancing pharmaceutical therapies for cancer and rare disease. The company's offerings span seven integrated service lines — Business Strategy, Engineering Solutions, Process & Analytical Development, Capital Projects, Supply Chain, Quality & Regulatory, and Operations Excellence — which together provide end-to-end support from early-stage development through commercial-scale manufacturing. Supporting these service lines are educational resources (the Radiopharma Brochure and Cyclotron Ebook), a dedicated ATMP Laboratory Services division for process and bioanalytical development, and a Workforce Development Center launching in 2026 to address talent gaps in advanced therapy manufacturing. The services are designed to be delivered in concert, with each capability reinforcing the others to enable clients to move therapies from concept to commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• Business Strategy Consulting Strategic consulting service helping advanced therapy developers align business strategies, regulatory approaches, engineering processes, and go-to-market plans; designed for pharmaceutical and biotech companies in nuclear medicine, radiation oncology, cell and gene therapy, regenerative medicine, and biotechnology.
• Engineering Solutions Engineering consulting supporting facility design, construction, and optimization for advanced therapy manufacturing, including hot cells, cyclotrons, isolators, containment systems, and process skids; intended for pharmaceutical and biotech companies building advanced therapy facilities.
• Process & Analytical Development Technical consulting for process development and analytical method development across cell therapy, gene therapy, and radiopharmaceuticals from conception through commercialization; aimed at developers needing manufacturing process and analytical readiness.
• Capital Projects End-to-end capital project solutions for specialized advanced therapy facilities, taking projects from feasibility studies through cGMP qualification while optimizing regulatory compliance, costs, and timelines; intended for pharmaceutical and biotech developers building or expanding manufacturing capacity.
• Supply Chain Consulting Supply chain planning and optimization for radiopharmaceutical and advanced therapy programs, including isotope sourcing strategy for Ac-225, Lu-177, and Pb-212; serves developers needing reliable access to scarce isotopes and raw materials.
• Quality & Regulatory Services Comprehensive quality, compliance, and regulatory affairs services including FDA compliance, ICH standards alignment, GMP audits, quality management system implementation, regulatory pathway development, and IND/IMPD/BLA submission support; serves developers of advanced therapies including radiopharmaceuticals, cell and gene therapies, and biologics.
• Operations Excellence Consulting to drive operational efficiency, scalable processes, and repeatable execution frameworks for GMP-regulated advanced therapy manufacturing environments; serves developers scaling from clinical to commercial production.
• ATMP Laboratory Services Process and analytical development and laboratory services for advanced therapeutic medicinal products (ATMPs) including cell therapy, gene therapy, and biologics; covers bioanalytical assays such as potency assays, flow cytometry, cell-based assays, and cell banking for developers needing laboratory support.
• Workforce Development Center A specialized workforce development platform providing hands-on training for operations, quality control, and quality assurance roles in cell and gene therapy, radiopharmaceutical manufacturing, and nuclear medicine production; co-located with Orchestra's Philadelphia Navy Yard headquarters and aimed at addressing the nationwide shortage of production operators and QA/QC technicians.
• TAG1 Generator A proprietary generator designed to unlock the supply of Lead-212 (Pb-212) for pre-clinical and clinical trials of targeted alpha therapies in cancer treatment; supports Orchestra's radiopharmaceutical clients and partners such as Precirix.

Quantifiable outcome

• Expanded from 4-person team to 60+ employees and consultants within 3 years
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• BioCentriqcoreImplementation/ SI/ Consulting Partner · 14 January 2025Strategic partnership to support BioCentriq's Princeton, NJ cell therapy facility development. Orchestra provides comprehensive technical expertise for facility design, implementation of advanced manufacturing technologies, development of integrated digital ecosystem, and optimization of facility design to meet FDA and EU GMP regulatory requirements. The collaboration supports BioCentriq's $12M CAPEX investment for facility optimization and digital integration to enhance cell therapy development and GMP manufacturing capabilities.
• Life CourierscoreStrategic or Co-development Partner · 17 September 2024Strategic partnership to enhance supply chain capabilities for the distribution of life-saving cancer treatments. Life Couriers, a global leader in specialized healthcare logistics, brings expertise in time-sensitive transport of medical isotopes and radiopharmaceuticals. The partnership leverages Life Couriers' global logistics network and Control Towers for real-time monitoring to streamline logistics between therapy developers and patients, minimizing delays and ensuring timely delivery of advanced therapies.
• PrecirixcoreStrategic or Co-development Partner · 8 July 2024Strategic collaboration to expand access to Lead-212 (Pb-212) radioisotope for targeted alpha therapy in cancer treatment. Orchestra's TAG1 generator is designed to unlock Pb-212 supply for pre-clinical and clinical trials. The partnership combines Precirix's precision radiopharmaceutical expertise using camelid single-domain antibodies with Orchestra's proficiency in isotope production, driving new R&D initiatives and breakthroughs in cancer therapy.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Parexel: Large global CRO offering regulatory consulting, CMC, clinical development, and commercialization services. Overlaps with Orchestra's regulatory and CMC work, but at vastly greater scale and across broader therapeutic areas.
• IQVIA: World's largest CRO with broad regulatory, quality, and technology services for pharma. Comparable on regulatory/CMC consulting but serves a much wider client base and modality set than Orchestra.
• Exyte: Global high-tech facility engineering and construction firm with a large life sciences practice. Comparable to Orchestra's Engineering Solutions and Capital Projects offerings for GMP and radiopharma facility builds, but at materially greater scale.

Direct peers

• ProPharma Group: Regulatory, compliance, and quality consulting firm supporting pharma, biotech, and medical device companies. Closely matches Orchestra's CMC/regulatory and quality systems offering for advanced therapy developers.
• CRB: Engineering, architecture, and consulting firm specializing in life sciences facility design and construction. Directly comparable to Orchestra's Engineering Solutions, Capital Projects, and Operations Excellence service lines, especially for advanced therapy and GMP facility work.
• Precision for Medicine: Specialized services and CDMO supporting radiopharmaceutical, cell therapy, and biomarker-driven programs. Directly comparable to Orchestra's radiopharma and cell/gene therapy manufacturing consulting practice.
• NDA Group: Independent regulatory and CMC consulting firm serving pharma and biotech globally. Comparable to Orchestra's Quality & Regulatory and Process & Analytical Development services, particularly for novel modalities and ATMPs.
• Pharmalex: Regulatory affairs and quality compliance consulting firm serving pharma and biotech. Comparable to Orchestra's Quality & Regulatory Services line, including CMC, IND/IMPD/BLA support, and GxP compliance work.
• Arcondis Group: Life sciences consulting firm offering regulatory, quality, engineering, and digital services to pharma and biotech. Overlaps with Orchestra's integrated seven-service platform for advanced therapy manufacturers.

Emerging players

• Skillpad: Life sciences training and workforce development provider for pharma manufacturing. Comparable to Orchestra's planned Workforce Development Center for cell/gene therapy and radiopharma operators, although Skillpad is more established in the UK and Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/orchestralifesciences
• LinkedInlinkedin.com/company/orchestra-life-sciences
• YouTubeyoutube.com/@orchestralifesciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orchestra Life Sciences